Liver Cancer Diagnostics Market Overview 2025 – Actionable Insights for Business Leaders

 Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

 
 How has the liver cancer diagnostics grown historically, and what trends indicate future expansion?
 The liver cancer diagnostics market size has grown strongly in recent years. It will grow from$9.69 billion in 2024 to $10.4 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to biopsy techniques and histopathology, development of biomarker detection, evolution of screening programs, advances in genetic testing, improvements in liver imaging modalities
 
 The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to “$13.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to regulatory changes and standardization, growing importance of imaging modalities, development of next-generation sequencing, expanded screening programs and awareness, rising demand for biomarker-based testing. Major trends in the forecast period include rise in incidence and prevalence, advancements in imaging technologies, focus on non-invasive diagnostics, precision medicine and personalized diagnostics, integration of artificial intelligence (AI).
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp
 
 Which key factors are driving the expansion of the liver cancer diagnostics industry?
 The rising prevalence of liver cancer is expected to propel the growth of the liver cancer diagnostics market going forward. Liver cancer refers to the condition in which the liver cells grow and multiply out of control, giving rise to a life-threatening illness. Liver cancer diagnostic tests are performed to determine whether cancer cells are spreading within the liver or surrounding it after the diagnosis of primary carcinoma of the liver, so the rising prevalence of liver cancer boosts the liver cancer diagnostics market. For instance, in January 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society, a US-based voluntary health organization, the number of new cases of liver and intrahepatic bile duct cancer in females reached 13,230 in 2023, an increase from 12,640 in 2020, in the United States. Furthermore, in 2023, an estimated 41,210 new cases of liver cancer will be diagnosed in the US, where 29,380 people are expected to die. Therefore, the rising prevalence of liver cancer is driving the growth of the liver cancer diagnostic market.
 
 How is the liver cancer diagnostics market segmented by product, application, and end-user?
 The liver cancer diagnostics market covered in this report is segmented –
 
 1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
 2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
 3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
 4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories
 
 Subsegments:
 1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
 3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma
 4) Other Types: Secondary Liver Cancer, Fibrolamellar Carcinoma
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report
 
 Which sustainability trends are emerging in the liver cancer diagnostics market?
 Major companies operating in the liver cancer diagnostics market are developing advanced biomarker-based assays and algorithms to improve diagnostic accuracy and support early detection. Biomarker-based assays and algorithms refer to diagnostic tools that utilize specific biological markers to identify diseases, providing more precise and efficient diagnostic capabilities. For instance, in November 2023, Roche Diagnostics, a US-based biotech corporation, launched the Elecsys PIVKA-II assay and Elecsys GAAD algorithm. The Elecsys PIVKA-II assay detects elevated levels of the PIVKA-II biomarker, which is associated with hepatocellular carcinoma (HCC), improving early detection of liver cancer in high-risk patients. The Elecsys GAAD algorithm integrates multiple diagnostic markers, such as PIVKA-II and AFP, to enhance diagnostic precision and streamline decision-making in liver cancer detection.
 
 Which leading companies are dominating the liver cancer diagnostics market landscape?
 Major companies operating in the liver cancer diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp
 
 Which geographic areas are expected to offer the highest growth opportunities in theliver cancer diagnostics market?
 North America was the largest region in the liver cancer diagnostics market in 2024. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 How Can Companies Use The Liver Cancer Diagnostics Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10481
 
 Need Customized Data On Liver Cancer Diagnostics Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=10481&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company